359 related articles for article (PubMed ID: 15793249)
21. Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue.
Kolterman OG; Gottlieb A; Moyses C; Colburn W
Diabetes Care; 1995 Aug; 18(8):1179-82. PubMed ID: 7587855
[TBL] [Abstract][Full Text] [Related]
22. Pramlintide reduces the risks associated with glucose variability in type 1 diabetes.
Kovatchev BP; Crean J; McCall A
Diabetes Technol Ther; 2008 Oct; 10(5):391-6. PubMed ID: 18715216
[TBL] [Abstract][Full Text] [Related]
23. Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone.
Edelman SV; Weyer C
Diabetes Technol Ther; 2002; 4(2):175-89. PubMed ID: 12079621
[TBL] [Abstract][Full Text] [Related]
24. Effect of Pramlintide on Postprandial Glucose Fluxes in Type 1 Diabetes.
Hinshaw L; Schiavon M; Dadlani V; Mallad A; Dalla Man C; Bharucha A; Basu R; Geske JR; Carter RE; Cobelli C; Basu A; Kudva YC
J Clin Endocrinol Metab; 2016 May; 101(5):1954-62. PubMed ID: 26930181
[TBL] [Abstract][Full Text] [Related]
25. Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes.
Galderisi A; Sherr J; VanName M; Carria L; Zgorski M; Tichy E; Weyman K; Cengiz E; Weinzimer S; Tamborlane W
J Clin Endocrinol Metab; 2018 Mar; 103(3):1088-1094. PubMed ID: 29211871
[TBL] [Abstract][Full Text] [Related]
26. Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes.
Pullman J; Darsow T; Frias JP
Vasc Health Risk Manag; 2006; 2(3):203-12. PubMed ID: 17326327
[TBL] [Abstract][Full Text] [Related]
27. Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm.
Renukuntla VS; Ramchandani N; Trast J; Cantwell M; Heptulla RA
J Diabetes Sci Technol; 2014 Sep; 8(5):1011-7. PubMed ID: 25030181
[TBL] [Abstract][Full Text] [Related]
28. Pramlintide acetate.
McQueen J
Am J Health Syst Pharm; 2005 Nov; 62(22):2363-72. PubMed ID: 16278328
[TBL] [Abstract][Full Text] [Related]
29. Pramlintide in the treatment of diabetes mellitus.
Edelman S; Maier H; Wilhelm K
BioDrugs; 2008; 22(6):375-86. PubMed ID: 18998755
[TBL] [Abstract][Full Text] [Related]
30. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.
Hollander PA; Levy P; Fineman MS; Maggs DG; Shen LZ; Strobel SA; Weyer C; Kolterman OG
Diabetes Care; 2003 Mar; 26(3):784-90. PubMed ID: 12610038
[TBL] [Abstract][Full Text] [Related]
31. Minimal reduction in insulin dosage with pramlintide therapy when pretreatment near-normal glycemia is established and square-wave meal bolus is used.
King AB
Endocr Pract; 2009 Apr; 15(3):229-33. PubMed ID: 19364691
[TBL] [Abstract][Full Text] [Related]
32. Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes.
Ceriello A; Piconi L; Quagliaro L; Wang Y; Schnabel CA; Ruggles JA; Gloster MA; Maggs DG; Weyer C
Diabetes Care; 2005 Mar; 28(3):632-7. PubMed ID: 15735200
[TBL] [Abstract][Full Text] [Related]
33. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control.
Weyer C; Maggs DG; Young AA; Kolterman OG
Curr Pharm Des; 2001 Sep; 7(14):1353-73. PubMed ID: 11472273
[TBL] [Abstract][Full Text] [Related]
34. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
Tsuchimochi W; Ueno H; Yamashita E; Tsubouchi C; Sakoda H; Nakamura S; Nakazato M
Endocr J; 2015; 62(1):13-20. PubMed ID: 25252844
[TBL] [Abstract][Full Text] [Related]
35. Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes.
Weinzimer SA; Sherr JL; Cengiz E; Kim G; Ruiz JL; Carria L; Voskanyan G; Roy A; Tamborlane WV
Diabetes Care; 2012 Oct; 35(10):1994-9. PubMed ID: 22815298
[TBL] [Abstract][Full Text] [Related]
36. A model of glucose-insulin-pramlintide pharmacokinetics and pharmacodynamics in type I diabetes.
Ramkissoon CM; Aufderheide B; Bequette BW; Palerm CC
J Diabetes Sci Technol; 2014 May; 8(3):529-42. PubMed ID: 24876617
[TBL] [Abstract][Full Text] [Related]
37. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes.
Edelman S; Garg S; Frias J; Maggs D; Wang Y; Zhang B; Strobel S; Lutz K; Kolterman O
Diabetes Care; 2006 Oct; 29(10):2189-95. PubMed ID: 17003291
[TBL] [Abstract][Full Text] [Related]
38. ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes.
Andersen G; Meiffren G; Famulla S; Heise T; Ranson A; Seroussi C; Eloy R; Gaudier M; Charvet R; Chan YP; Soula O; DeVries JH
Diabetes Obes Metab; 2021 Apr; 23(4):961-970. PubMed ID: 33336850
[TBL] [Abstract][Full Text] [Related]
39. Amylin and glycaemic regulation: a possible role for the human amylin analogue pramlintide.
Kolterman OG
Diabet Med; 1997 Jun; 14 Suppl 2():S35-8. PubMed ID: 9212328
[TBL] [Abstract][Full Text] [Related]
40. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.
Whitehouse F; Kruger DF; Fineman M; Shen L; Ruggles JA; Maggs DG; Weyer C; Kolterman OG
Diabetes Care; 2002 Apr; 25(4):724-30. PubMed ID: 11919132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
